

antagonists, growth factors, opioid antagonists, phosphatidylcholine precursors, serotonin agonists, sodium- and calcium-channel blockers, and potassium channel openers.

195. (Amended) The method of claim 193, wherein the agent having a site of action in the brain is selected from the group consisting of analeptic, analgesic, anesthetic, adrenergic agent, anti-adrenergic agent, adrenocortical steroid, amino acids, antagonists, antidote, anti-anxiety agent, anticholinergic, anticoagulant, anticolvulsant, antidepressant, anti-emetic, anti-epileptic, antihypertensive, antifibrinolytic, antihyperlipidemic, anti-inflammatory, antimigraine, antinauseant, antineoplastic (brain cancer), antiofessional agent, antiparkinsonian, antiproliferative, antipsychotic, antithrombotic, appetite suppressant, blood glucose regulator, cognition adjuvant, cognition enhancer, cholinergic agonist, dopaminergic agent, emetic, estrogen, fibrinolytic, free oxygen radical scavenger, glucocorticoid, hypocholesterolemic, holylipidemic, histamine H<sub>2</sub> receptor antagonists, immunosuppressant, inhibitor, memory adjuvant, mental performance enhancer, mood regulator, mydriatic, neuromuscular blocking agent, neuroprotective, NMDA antagonist, plasminogen activator, post-stroke and post-head trauma treatment, psychotropic, sedative, sedative-hypnotic, serotonin inhibitor, steroid, tranquilizer, and treatment of cerebral ischemia, calcium channel blockers, free radical scavengers – antioxidants, GABA agonists, glutamate antagonists, AMPA antagonists, kainate antagonists, competitive and non-competitive NMDA antagonists, growth factors, opioid antagonists, phosphatidylcholine precursors, serotonin agonists, sodium- and calcium-channel blockers, and potassium channel openers.

#### REMARKS

Claims 194 and 195 are amended to add certain categories of agents not previously claimed. This is identical to the claim 196 amendment previously submitted (on 12/13/00). Support for this amendment can be found at least in pages 22 - 24 of the specification.

If the Examiner has any questions and believes that a telephone conference with Applicants' attorney would prove helpful in expediting the prosecution of this application, the Examiner is urged to call the undersigned at (617) 720-3500 (Extension 286).

Respectfully submitted,

*Konstantinos Andrikopoulos*

Konstantinos Andrikopoulos, Reg. No. 48,915  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211

Docket No. R0547/7007 (ERG/KA)

Date: February 21, 2002

xNDD

MARKED-UP CLAIMS

194. (Amended) The method of claim 192, wherein the second agent is selected from the group consisting of analeptic, analgesic, anesthetic, adrenergic agent, anti-adrenergic agent, adrenocortical steroid, amino acids, antagonists, antidote, anti-anxiety agent, anticholinergic, anticoagulant, anticolvulsant, antidepressant, anti-emetic, anti-epileptic, antihypertensive, antifibrinolytic, antihyperlipidemic, anti-inflammatory, antimigraine, antinauseant, antineoplastic (brain cancer), antioxibessional agent, antiparkinsonian, antiproliferative, antipsychotic, antithrombotic, appetite suppressant, blood glucose regulator, cognition adjuvant, cognition enhancer, cholinergic agonist, dopaminergic agent, emetic, estrogen, fibrinolytic, free oxygen radical scavenger, glucocorticoid, hypocholesterolemic, holylipidemic, histamine H2 receptor antagonists, immunosuppressant, inhibitor, memory adjuvant, mental performance enhancer, mood regulator, mydriatic, neuromuscular blocking agent, neuroprotective, NMDA antagonist, plasminogen activator, post-stroke and post-head trauma treatment, psychotropic, sedative, sedative-hypnotic, serotonin inhibitor, steroid, tranquilizer, and treatment of cerebral ischemia, calcium channel blockers, free radical scavengers – antioxidants, GABA agonists, glutamate antagonists, AMPA antagonists, kainate antagonists, competitive and non-competitive NMDA antagonists, growth factors, opioid antagonists, phosphatidylcholine precursors, serotonin agonists, sodium- and calcium-channel blockers, and potassium channel openers.

195. (Amended) The method of claim 193, wherein the agent having a site of action in the brain is selected from the group consisting of analeptic, analgesic, anesthetic, adrenergic agent, anti-adrenergic agent, adrenocortical steroid, amino acids, antagonists, antidote, anti-anxiety agent, anticholinergic, anticoagulant, anticolvulsant, antidepressant, anti-emetic, anti-epileptic, antihypertensive, antifibrinolytic, antihyperlipidemic, anti-inflammatory, antimigraine, antinauseant, antineoplastic (brain cancer), antioxibessional agent, antiparkinsonian, antiproliferative, antipsychotic, antithrombotic, appetite suppressant, blood glucose regulator, cognition adjuvant, cognition enhancer, cholinergic agonist, dopaminergic agent, emetic, estrogen, fibrinolytic, free oxygen radical scavenger, glucocorticoid, hypocholesterolemic, holylipidemic, histamine H2 receptor antagonists, immunosuppressant, inhibitor, memory adjuvant, mental performance enhancer, mood regulator, mydriatic, neuromuscular blocking agent, neuroprotective, NMDA antagonist, plasminogen activator, post-stroke and post-head trauma treatment, psychotropic, sedative, sedative-hypnotic, serotonin inhibitor, steroid, tranquilizer, and treatment of cerebral ischemia, calcium channel blockers, free radical scavengers – antioxidants, GABA agonists, glutamate antagonists, AMPA antagonists, kainate antagonists, competitive and non-competitive NMDA antagonists, growth factors, opioid antagonists, phosphatidylcholine precursors, serotonin agonists, sodium- and calcium-channel blockers, and potassium channel openers.